B cell abnormalities and therapeutic strategies in systemic sclerosis

Japanese Journal of Clinical Immunology

Volumn 39, Issue 3, 2016, Pages 197-206

  Yoshizaki, Ayumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

B cell; Belimumab; Rituximab; Systemic sclerosis

Indexed keywords

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL SURVIVAL; CYTOLOGY; HUMAN; PATHOGENESIS; REVIEW; SYSTEMIC SCLEROSIS; ANIMAL; ANTIBODY PRODUCTION; AUTOIMMUNITY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FIBROSIS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MOLECULARLY TARGETED THERAPY; MOUSE; PATHOLOGY; SCLERODERMA, SYSTEMIC;

AUTOANTIBODY; BELIMUMAB; CD20 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; ANTIGENS, CD20; AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; FIBROSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MICE; MOLECULAR TARGETED THERAPY; RITUXIMAB; SCLERODERMA, SYSTEMIC;

EID: 84975048507     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.39.197     Document Type: Review

References (40)

1. Engel, P., et al.: Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 3: 39-50, 1995.
2. Sato, S., et al: CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Proc Natl Acad Sci USA. 94: 13158-13162, 1997.
3. Yoshizaki, A., Sato, S.: Abnormal B lymphocyte activation and function in systemic sclerosis. Ann Dermatol. 27: 1-9, 2015.
4. Bouaziz, J.D., et al.: Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci USA. 104: 20878-20883, 2007.
5. Yanaba, K., et al.: B cell depletion delays collageninduced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J Immunol. 179: 1369-1380, 2007.
6. Xiu, Y., et al.: B lymphocytes depletion by CD20 monoclonal antibody prevents diabetes in NOD mice despite isotype-specific differences in FcγR effector functions. J Immunol. 180: 2863-2875, 2008.
7. Hayakawa, I., et al.: B-lymphocyte depletion ameliorates Sjogren’s syndrome in Id3 knockout mice. Immunology. 122: 73-79, 2007.
8. Hasegawa, M., et al.: B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tightskin mouse model for systemic sclerosis. Am J Pathol. 169: 954-966, 2006.
9. Lund, F.: Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol. 20: 332-338, 2008.
10. Leon, B., Lund, F.: IL-17-producing B cells combat parasites. Nat Immunol. 14: 419-421, 2013.
11. Shen, P., et al.: IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 507: 366-370, 2014.
12. Yanaba, K., et al.: A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity. 28: 639-650, 2008.
13. Iwata, Y., et al.: Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 117: 530-541, 2011.
14. Mizoguchi, A., Bhan, A.K.: A case for regulatory B cells. J Immunol. 176: 705-710, 2006.
15. Kalampokis, I., et al.: IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 15 suppl 1: S1-12, 2013.
16. Yoshizaki, A., et al.: Regulatory B cells control T-cell autoimmunity through IL-21-dependet cognate interactions. Nature. 491: 264-268, 2012.
17. Sato, S., et al.: Altered B lymphocyte function and systemic autoimmunity in systemic sclerosis. Mol Immunol. 41: 1123-1133, 2004.
18. Yoshizaki, A.: B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets. J Dermatol. 43: 39-45, 2016.
19. Tsuchiya, N., et al.: Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis (scleroderma). Arthritis Rheum. 50: 4002-4007, 2004.
20. Tedder, T.F., et al.: Structure of the gene encoding the human B lymphocyte differentiation antigen CD20 (B1). J Immunol. 142: 2560-2568, 1989.
21. Alas, S., et al.: Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res. 7: 709-723, 2001.
22. Clynes, R., et al.: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 6: 443-446, 2000.
23. Cragg, M., et al.: Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 101: 1045-1052, 2003.
24. Winkler, U., et al.: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood. 94: 2217-2224, 1999.
25. Emery, P., et al.: Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 69: 1629-1635, 2010.
26. Catapano, F., et al.: Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 25: 3586-3592, 2010.
27. Oddis, C.V., et al.: Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 65: 314-324, 2013.
28. Stone, J.H., et al.: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 363: 221-232, 2010.
29. Guillevin, L., et al.: Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 371: 1771-1780, 2014.
30. Smith, V., et al.: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 69: 193-197, 2010.
31. Lafyatis, R., et al.: B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 60: 578-583, 2009.
32. Daoussis, D., et al.: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 49: 271-280, 2010.
33. Daoussis, D., et al.: Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 30: S17-22, 2012.
34. Jordan, S., et al.: Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 74: 1188-1194, 2015
35. Bosello, S.L., et al.: Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 44: 428-436, 2015.
36. Von Bulow, G.U., et al.: Regulation of the Tindependent humoral response by TACI. Immunity. 14: 573-582, 2001.
37. Lesley, R., et al.: Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 20: 441-453, 2004.
38. Matsushita, T., et al.: Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 54: 192-201, 2006.
39. Elhai, M., et al.: Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis. 72: 1217-1220, 2013.
40. Fineschi, S., et al.: In vivo investigations on antifibrotic potential of proteasome inhibition in lung and skin fibrosis. Am J Respir Cell Mol Biol. 39: 458-465, 2008.